by Dan DeMarle | Jun 11, 2023 | ADHD, Attention Deficit Hyperactivity Disorder, Medicine, Other Health Impairment
Reports indicate the shortage might be the result of transparency issues among government agencies and drug manufacturers. On October 12, 2022, the FDA announced a shortage of the attention deficit hyperactivity disorder (ADHD) medication Adderall. At the time, the...
by Dan DeMarle | Jun 4, 2023 | Disability, Medicine
New research suggests that a subset of patients with psychiatric conditions like schizophrenia may actually have autoimmune disease that attacks the brain. By Richard Sima...
by Dan DeMarle | Feb 18, 2023 | ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, Medicine, Other Health Impairment
Stories about attention deficit hyperactivity disorder, or ADHD, have been having a resurgence in the social media zeitgeist the past several years, and it may be leading more people to seek out diagnosis for the condition. “A lot of my patients would hold up their...
by Dan DeMarle | Jan 10, 2023 | Health Care, Medicine, Obesity
Children with obesity should be offered more intensive treatment options earlier, including therapy and medication, says the leading U.S. pediatricians group. The American Academy of Pediatrics’ new guidance on childhood obesity — the first in 15 years — moves...
by Dan DeMarle | Jan 3, 2023 | Americans with Disability Act (ADA), Developmental Disability, Disability, Medicine
The 1990 Americans with Disabilities Act and subsequent ADA Amendments Act of 2008 mandated equal access to health care access to people with disabilities. But a new study finds many doctors still either unable or unwilling to provide the same level of care to...
by Dan DeMarle | Dec 19, 2022 | ADHD, Attention Deficit Hyperactivity Disorder, Medicine, Other Health Impairment
A growing U.S. shortage of Adderall, a prescription drug taken to treat attention deficit hyperactivity disorder, has spread to two more makers of the drug. Lannett Co. and Par Pharmaceuticals are the most recent companies experiencing with limited supplies of generic...
